News
AMRN
0.4487
-1.75%
-0.0080
Weekly Report: what happened at AMRN last week (1216-1220)?
Weekly Report · 3d ago
Amarin Appoints Peter Fishman as New CFO
TipRanks · 12/18 21:53
Amarin Corporation Announces National Reimbursement Approval for VAZKEPA® in Italy to Reduce Cardiovascular Risk in High-Risk Patients
Barchart · 12/16 16:20
AMARIN RECEIVES NATIONAL REIMBURSEMENT FOR VAZKEPA® IN ITALY
Reuters · 12/16 12:03
Weekly Report: what happened at AMRN last week (1209-1213)?
Weekly Report · 12/16 09:54
Executive reshuffles: JPM, QCOM, DVN and LTC
Seeking Alpha · 12/14 20:54
Amarin Corporation Appoints Peter Fishman as Chief Financial Officer
Barchart · 12/13 18:28
Amarin appoints CFO
Seeking Alpha · 12/13 14:12
Amarin appoints Fishman as Chief Financial Officer
TipRanks · 12/13 14:05
Amarin Appoints Peter Fishman CFO, Effective Immediately
Benzinga · 12/13 14:02
AMARIN APPOINTS PETER FISHMAN CHIEF FINANCIAL OFFICER
Reuters · 12/13 14:00
Weekly Report: what happened at AMRN last week (1202-1206)?
Weekly Report · 12/09 09:53
Weekly Report: what happened at AMRN last week (1125-1129)?
Weekly Report · 12/02 09:53
Weekly Report: what happened at AMRN last week (1118-1122)?
Weekly Report · 11/25 09:50
AMARIN CORP - NASDAQ GRANTED 180 DAYS TO REGAIN NASDAQ COMPLIANCE
Reuters · 11/22 21:52
After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN)
NASDAQ · 11/19 14:35
Top 3 Health Care Stocks You'll Regret Missing In Q4
Benzinga · 11/19 12:52
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Bolt Biotherapeutics (BOLT) and Amarin (AMRN)
TipRanks · 11/19 07:00
Weekly Report: what happened at AMRN last week (1111-1115)?
Weekly Report · 11/18 09:49
Amarin Corporation Announces That Investigators Will Present An Additional Subgroup Analysis From The REDUCE-IT Outcomes Trial In Patients With And Without Coronary Artery Disease History And Mechanistic Data On Eicosapentaenoic Acid At The American Heart Association's Scientific Sessions
Benzinga · 11/11 13:22
More
Webull provides a variety of real-time AMRN stock news. You can receive the latest news about Amarin through multiple platforms. This information may help you make smarter investment decisions.
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.